English
Insider transactions
EDGARApogee Therapeutics, Inc.
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.
A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.
Window: transactions dated on or after 2025-11-21.
- Open-market purchases (code P)
- 0 transactions, — shares
- Open-market sales (code S)
- 72 transactions, 2,149,000 shares
- Sum of shares × price per share: 171,914,127.22
Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.
Showing 1–50 of 151
| Date | Reporting owner | Code | Acquired or disposed | Shares | Price per share, as filed | Value (derived) | Shares owned after | Direct or indirect | Rule 10b5-1 box | Notes | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-03 Filed 2026-09-03 | Shah Nimish P Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 1,750,000 | 135.11 | 236,442,500Derived: shares × price per share. Exact value 236442500.00. | 0 | Indirect (I) See footnote | No | F1, F2
| Open filing 0001140361-26-035608 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | Shah Nimish P Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 6,743,321 | 135.11 | 911,090,100.31Derived: shares × price per share. Exact value 911090100.31. | 0 | Indirect (I) See footnote | No | F3, F4, F2
| Open filing 0001140361-26-035608 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | Shah Nimish P Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 47,758 | — | — | 0 | Direct (D) | No | F6, F5, F7
| Open filing 0001140361-26-035608 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | Shah Nimish P Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 10,370 | — | — | 0 | Direct (D) | No | F6, F5, F7
| Open filing 0001140361-26-035608 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | Shah Nimish P Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 14,461 | — | — | 0 | Direct (D) | No | F6, F5, F7
| Open filing 0001140361-26-035608 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | Shah Nimish P Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 7,657 | — | — | 0 | Direct (D) | No | F6, F5, F7
| Open filing 0001140361-26-035608 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | Shah Nimish P Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 365,853 | — | — | 0 | Indirect (I) See footnote | No | F8, F6, F9, F10
| Open filing 0001140361-26-035608 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | Bollinger Lisa Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 18,550 | — | — | 0 | Direct (D) | No | F2, F1
| Open filing 0001140361-26-035610 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | Bollinger Lisa Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 8,112 | — | — | 0 | Direct (D) | No | F2, F1
| Open filing 0001140361-26-035610 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | Bollinger Lisa Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 14,461 | — | — | 0 | Direct (D) | No | F2, F1
| Open filing 0001140361-26-035610 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | Bollinger Lisa Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 7,657 | — | — | 0 | Direct (D) | No | F2, F1
| Open filing 0001140361-26-035610 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | Fox Jennifer A. Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 34,824 | — | — | 0 | Direct (D) | No | F1
| Open filing 0001140361-26-035612 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | Fox Jennifer A. Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 10,370 | — | — | 0 | Direct (D) | No | F3, F2
| Open filing 0001140361-26-035612 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | Fox Jennifer A. Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 14,461 | — | — | 0 | Direct (D) | No | F3, F2
| Open filing 0001140361-26-035612 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | Fox Jennifer A. Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 7,657 | — | — | 0 | Direct (D) | No | F3, F2
| Open filing 0001140361-26-035612 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | HENDERSON MICHAEL THOMAS Director · Officer: Chief Executive Officer | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 920,941 | — | — | 0 | Direct (D) | No | F1
| Open filing 0001140361-26-035609 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | HENDERSON MICHAEL THOMAS Director · Officer: Chief Executive Officer | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 387,012 | — | — | 0 | Direct (D) | No | F3, F2
| Open filing 0001140361-26-035609 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | HENDERSON MICHAEL THOMAS Director · Officer: Chief Executive Officer | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 357,036 | — | — | 0 | Direct (D) | No | F3, F2
| Open filing 0001140361-26-035609 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | HENDERSON MICHAEL THOMAS Director · Officer: Chief Executive Officer | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 253,016 | — | — | 0 | Direct (D) | No | F3, F2
| Open filing 0001140361-26-035609 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | Dambkowski Carl Officer: Chief Medical Officer | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 167,123 | — | — | 0 | Direct (D) | No | F1
| Open filing 0001140361-26-035613 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | Dambkowski Carl Officer: Chief Medical Officer | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 110,665 | — | — | 0 | Direct (D) | No | F3, F2
| Open filing 0001140361-26-035613 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | Dambkowski Carl Officer: Chief Medical Officer | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 124,962 | — | — | 0 | Direct (D) | No | F3, F2
| Open filing 0001140361-26-035613 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | Dambkowski Carl Officer: Chief Medical Officer | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 83,690 | — | — | 0 | Direct (D) | No | F3, F2
| Open filing 0001140361-26-035613 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | Fairmount Funds Management LLC DirectorFairmount Healthcare Fund II L.P. DirectorKiselak Tomas DirectorHarwin Peter Evan Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 340,855 | — | — | 0 | Indirect (I) By Fairmount Healthcare Fund II LP | No | F1, F2
| Open filing 0001104659-26-105119 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | Fairmount Funds Management LLC DirectorFairmount Healthcare Fund II L.P. DirectorKiselak Tomas DirectorHarwin Peter Evan Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 51,166 | — | — | 0 | Indirect (I) By Tomas Kiselak | No | F1
| Open filing 0001104659-26-105119 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | Fairmount Funds Management LLC DirectorFairmount Healthcare Fund II L.P. DirectorKiselak Tomas DirectorHarwin Peter Evan Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 51,166 | — | — | 0 | Indirect (I) By Peter Harwin | No | F1
| Open filing 0001104659-26-105119 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | Fairmount Funds Management LLC DirectorFairmount Healthcare Fund II L.P. DirectorKiselak Tomas DirectorHarwin Peter Evan Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 6,743,321 | — | — | 0 | Indirect (I) By Fairmount Healthcare Fund II LP | No | F3, F1, F2
| Open filing 0001104659-26-105119 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | Fairmount Funds Management LLC DirectorFairmount Healthcare Fund II L.P. DirectorKiselak Tomas DirectorHarwin Peter Evan Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 47,758 | — | — | 0 | Indirect (I) By Tomas Kiselak | No | F5, F4, F6
| Open filing 0001104659-26-105119 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | Fairmount Funds Management LLC DirectorFairmount Healthcare Fund II L.P. DirectorKiselak Tomas DirectorHarwin Peter Evan Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 10,370 | — | — | 0 | Indirect (I) By Tomas Kiselak | No | F5, F4, F6
| Open filing 0001104659-26-105119 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | Fairmount Funds Management LLC DirectorFairmount Healthcare Fund II L.P. DirectorKiselak Tomas DirectorHarwin Peter Evan Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 14,461 | — | — | 0 | Indirect (I) By Tomas Kiselak | No | F5, F4, F6
| Open filing 0001104659-26-105119 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | Fairmount Funds Management LLC DirectorFairmount Healthcare Fund II L.P. DirectorKiselak Tomas DirectorHarwin Peter Evan Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 7,657 | — | — | 0 | Indirect (I) By Tomas Kiselak | No | F5, F4, F6
| Open filing 0001104659-26-105119 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | McKenna Mark C. Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 20,000 | — | — | 0 | Direct (D) | No | F1
| Open filing 0001140361-26-035615 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | McKenna Mark C. Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 150,000 | — | — | 0 | Direct (D) | No | F3, F2
| Open filing 0001140361-26-035615 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | McKenna Mark C. Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 10,370 | — | — | 0 | Direct (D) | No | F3, F2
| Open filing 0001140361-26-035615 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | McKenna Mark C. Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 14,461 | — | — | 0 | Direct (D) | No | F3, F2
| Open filing 0001140361-26-035615 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | McKenna Mark C. Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 7,657 | — | — | 0 | Direct (D) | No | F3, F2
| Open filing 0001140361-26-035615 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | JONES WILLIAM A JR Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 34,824 | — | — | 0 | Direct (D) | No | F1
| Open filing 0001140361-26-035614 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | JONES WILLIAM A JR Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 10,370 | — | — | 0 | Direct (D) | No | F3, F2
| Open filing 0001140361-26-035614 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | JONES WILLIAM A JR Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 14,461 | — | — | 0 | Direct (D) | No | F3, F2
| Open filing 0001140361-26-035614 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | JONES WILLIAM A JR Director | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 7,657 | — | — | 0 | Direct (D) | No | F3, F2
| Open filing 0001140361-26-035614 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | Henderson Jane Officer: Chief Financial Officer | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 158,371 | — | — | 0 | Direct (D) | No | F1
| Open filing 0001140361-26-035611 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | Henderson Jane Officer: Chief Financial Officer | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 175,345 | — | — | 0 | Direct (D) | No | F3, F2
| Open filing 0001140361-26-035611 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | Henderson Jane Officer: Chief Financial Officer | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 124,962 | — | — | 0 | Direct (D) | No | F3, F2
| Open filing 0001140361-26-035611 Read from the filing’s XML Dispute this row |
| 2026-09-03 Filed 2026-09-03 | Henderson Jane Officer: Chief Financial Officer | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 83,690 | — | — | 0 | Direct (D) | No | F3, F2
| Open filing 0001140361-26-035611 Read from the filing’s XML Dispute this row |
| 2026-09-02 Filed 2026-09-03 | Dambkowski Carl Officer: Chief Medical Officer | DDisposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | Disposed (D) | 1,375 | 135.06 | 185,707.5Derived: shares × price per share. Exact value 185707.50. | 167,123 | Direct (D) | No | — | Open filing 0001140361-26-035613 Read from the filing’s XML Dispute this row |
| 2026-08-07 Filed 2026-08-11 | Fairmount Funds Management LLC DirectorFairmount Healthcare Fund II L.P. DirectorKiselak Tomas DirectorHarwin Peter Evan Director | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 31,838 | 17.00 | 541,246Derived: shares × price per share. Exact value 541246.00. | 330,485 | Indirect (I) By Fairmount Healthcare Fund II LP | No | F1
| Open filing 0001104659-26-094087 Read from the filing’s XML Dispute this row |
| 2026-08-07 Filed 2026-08-11 | Fairmount Funds Management LLC DirectorFairmount Healthcare Fund II L.P. DirectorKiselak Tomas DirectorHarwin Peter Evan Director | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 10,370 | 43.85 | 454,724.5Derived: shares × price per share. Exact value 454724.50. | 340,855 | Indirect (I) By Fairmount Healthcare Fund II LP | No | F1
| Open filing 0001104659-26-094087 Read from the filing’s XML Dispute this row |
| 2026-08-07 Filed 2026-08-11 | Fairmount Funds Management LLC DirectorFairmount Healthcare Fund II L.P. DirectorKiselak Tomas DirectorHarwin Peter Evan Director | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 31,838 | 0 | — | 0 | Direct (D) | No | F2, F3
| Open filing 0001104659-26-094087 Read from the filing’s XML Dispute this row |
| 2026-08-07 Filed 2026-08-11 | Fairmount Funds Management LLC DirectorFairmount Healthcare Fund II L.P. DirectorKiselak Tomas DirectorHarwin Peter Evan Director | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 10,370 | 0 | — | 0 | Direct (D) | No | F4, F3
| Open filing 0001104659-26-094087 Read from the filing’s XML Dispute this row |
| 2026-08-05 Filed 2026-08-07 | Dambkowski Carl Officer: Chief Medical Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 4,125 | 22.86 | 94,297.5Derived: shares × price per share. Exact value 94297.50. | 173,998 | Direct (D) | Yes | — | Open filing 0001104659-26-092838 Read from the filing’s XML Dispute this row |
Institutional holders (Form 13F)
Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.
Showing 1–4 of 4
| Manager | Shares or principal | Value as filed | Change from the prior quarter | Source |
|---|---|---|---|---|
| GLENMEDE TRUST CO NA | 8,127 SH | 322,885 dollars | Higher by 2,007 Prior quarter: 6,120 | Open filing 0001398344-26-020129 Filed 2026-11-16 Dispute this row |
| TEACHER RETIREMENT SYSTEM OF TEXAS | 4,423 SH | 587,065 dollars | Unchanged Prior quarter: 4,423 | Open filing 0000796848-26-000014 Filed 2026-11-12 Dispute this row |
| IFP Advisors, Inc Partly reported under another manager | 79 SH | 10,671 dollars | Higher by 7 Prior quarter: 72 | Open filing 0001641866-26-000005 Filed 2026-10-16 Dispute this row |
| Allworth Financial LP | 16 SH | 2,124 dollars | Unchanged Prior quarter: 16 | Open filing 0001140361-26-042358 Filed 2026-11-06 Dispute this row |
Managers in the prior quarter with no filing read for the latest
They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.
- Venrock Adviser, LLC 8,493,321 SH
- BlackRock, Inc. 5,507,032 SH
- HBK INVESTMENTS L P 2,850,000 SH
- VANGUARD CAPITAL MANAGEMENT LLC 2,572,119 SH
- FMR LLC 2,493,137 SH
- STATE STREET CORP 2,297,743 SH
- Driehaus Capital Management LLC 1,740,101 SH
- GOLDMAN SACHS GROUP INC 1,693,341 SH
- Balyasny Asset Management L.P. 1,665,102 SH
- GLAZER CAPITAL, LLC 1,641,042 SH
- Paradigm Biocapital Advisors LP 1,576,385 SH
- VANGUARD PORTFOLIO MANAGEMENT LLC 1,528,750 SH
- MILLENNIUM MANAGEMENT LLC 1,491,404 SH
- Pentwater Capital Management LP 1,425,000 SH
- MORGAN STANLEY 1,421,681 SH
- GEODE CAPITAL MANAGEMENT, LLC 1,314,868 SH
- PERCEPTIVE ADVISORS LLC 1,308,113 SH
- Jupiter Topco LLC 1,193,626 SH
- BANK OF AMERICA CORP /DE/ 1,126,139 SH
- Affinity Asset Advisors, LLC 987,000 SH
- MERCER GLOBAL ADVISORS INC /ADV 941,283 SH
- First Light Asset Management, LLC 930,289 SH
- O'Connor Alternative Investments, LLC 875,000 SH
- ALLIANCEBERNSTEIN L.P. 775,058 SH
- T. Rowe Price Investment Management, Inc. 762,183 SH
- Kryger Capital LLC 742,555 SH
- Qube Research Technologies Ltd 659,678 SH
- First Trust Capital Management L.P. 625,182 SH
- Remedium Capital Partners, LLC 586,691 SH
- SOROS FUND MANAGEMENT LLC 564,500 SH
- WELLINGTON MANAGEMENT GROUP LLP 564,326 SH
- Balyasny Asset Management L.P. 500,000 SH
- Woodline Partners LP 464,622 SH
- WHITEBOX ADVISORS LLC 450,001 SH
- NORTHERN TRUST CORP 445,154 SH
- Sixth Street Partners Management Company, L.P. 443,658 SH
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC 443,658 SH
- AQR Arbitrage LLC 429,900 SH
- Magnetar Financial LLC 399,123 SH
- Man Group plc 397,000 SH
- VANGUARD FIDUCIARY TRUST CO 393,180 SH
- Opaleye Management Inc. 390,000 SH
- TIG Advisors, LLC 364,250 SH
- FRANKLIN RESOURCES INC 363,379 SH
- JPMORGAN CHASE CO 359,250 SH
- Cinctive Capital Management LP 350,165 SH
- LOOMIS SAYLES CO L P 338,664 SH
- Polar Asset Management Partners Inc. 322,467 SH
- FRONTIER CAPITAL MANAGEMENT CO LLC 303,739 SH
- NEXPOINT ASSET MANAGEMENT, L.P. 299,940 SH
- Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
- Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
- A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
- A change is the difference between two quarter-end snapshots, not a trade.
- A position reported under another manager may also appear in that manager’s filing; rows are not added together.
- Holdings the securities list cannot place with this company, or places ambiguously, are not shown.
Trades by members of Congress
Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.
No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.
5% holders (Schedule 13D and 13G)
Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.
| Holder | Percent of class | Shares held | Event date | Form | Source |
|---|---|---|---|---|---|
| Venrock Healthcare Capital Partners III, L.P. Common Stock, par value $0.00001 per share | 0.0 | 0.00 | 09/03/2026 Filed 2026-09-08 | SCHEDULE 13D/AAmendment 1 | Open filing 0001231919-26-001150 Dispute this row |
| VHCP Co-Investment Holdings III, LLC Common Stock, par value $0.00001 per share | 0.0 | 0.00 | 09/03/2026 Filed 2026-09-08 | SCHEDULE 13D/AAmendment 1 | Open filing 0001231919-26-001150 Dispute this row |
| Venrock Healthcare Capital Partners EG, L.P. Common Stock, par value $0.00001 per share | 0.0 | 0.00 | 09/03/2026 Filed 2026-09-08 | SCHEDULE 13D/AAmendment 1 | Open filing 0001231919-26-001150 Dispute this row |
| VHCP Management III, LLC Common Stock, par value $0.00001 per share | 0.0 | 0.00 | 09/03/2026 Filed 2026-09-08 | SCHEDULE 13D/AAmendment 1 | Open filing 0001231919-26-001150 Dispute this row |
| VHCP Management EG, LLC Common Stock, par value $0.00001 per share | 0.0 | 0.00 | 09/03/2026 Filed 2026-09-08 | SCHEDULE 13D/AAmendment 1 | Open filing 0001231919-26-001150 Dispute this row |
| Bong Y. Koh Common Stock, par value $0.00001 per share | 0.0 | 0.00 | 09/03/2026 Filed 2026-09-08 | SCHEDULE 13D/AAmendment 1 | Open filing 0001231919-26-001150 Dispute this row |
| Nimish Shah Common Stock, par value $0.00001 per share | 0.0 | 0.00 | 09/03/2026 Filed 2026-09-08 | SCHEDULE 13D/AAmendment 1 | Open filing 0001231919-26-001150 Dispute this row |
| Fairmount Funds Management LLC Common Stock, $0.00001 par value | 0.0 | 0.00 | 09/03/2026 Filed 2026-09-03 | SCHEDULE 13D/AAmendment 7 | Open filing 0001104659-26-105122 Dispute this row |
| Fairmount Healthcare Fund II L.P. Common Stock, $0.00001 par value | 0.0 | 0.00 | 09/03/2026 Filed 2026-09-03 | SCHEDULE 13D/AAmendment 7 | Open filing 0001104659-26-105122 Dispute this row |
| Peter Evan Harwin Common Stock, $0.00001 par value | 0.0 | 0.00 | 09/03/2026 Filed 2026-09-03 | SCHEDULE 13D/AAmendment 7 | Open filing 0001104659-26-105122 Dispute this row |
| Tomas Kiselak Common Stock, $0.00001 par value | 0.0 | 0.00 | 09/03/2026 Filed 2026-09-03 | SCHEDULE 13D/AAmendment 7 | Open filing 0001104659-26-105122 Dispute this row |
| FMR LLC COMMON STOCK | 4.0 | 2,493,136.73 | 06/30/2026 Filed 2026-07-08 | SCHEDULE 13G/AAmendment 4 | Open filing 0000315066-26-001471 Dispute this row |
| Abigail P. Johnson COMMON STOCK | 4.0 | 2,493,136.73 | 06/30/2026 Filed 2026-07-08 | SCHEDULE 13G/AAmendment 4 | Open filing 0000315066-26-001471 Dispute this row |
| T. Rowe Price Investment Management, Inc. COMMON STOCK | 1.3 | 772,969 | 06/30/2026 Filed 2026-07-08 | SCHEDULE 13G/AAmendment 2 | Open filing 0001897612-26-000527 Dispute this row |
| Wellington Management Group LLP Common Stock | 0.9 | 564,326.00 | 06/30/2026 Filed 2026-07-08 | SCHEDULE 13G/AAmendment 5 | Open filing 0000902219-26-000212 Dispute this row |
| Wellington Group Holdings LLP Common Stock | 0.9 | 564,326.00 | 06/30/2026 Filed 2026-07-08 | SCHEDULE 13G/AAmendment 5 | Open filing 0000902219-26-000212 Dispute this row |
| Wellington Investment Advisors Holdings LLP Common Stock | 0.9 | 564,326.00 | 06/30/2026 Filed 2026-07-08 | SCHEDULE 13G/AAmendment 5 | Open filing 0000902219-26-000212 Dispute this row |
| Fairmount Funds Management LLC Common Stock, $0.00001 par value | 9.84 | 6,713,519.00 | 06/18/2026 Filed 2026-06-23 | SCHEDULE 13D/AAmendment 6 | Open filing 0001104659-26-076853 Dispute this row |
| Fairmount Healthcare Fund II L.P. Common Stock, $0.00001 par value | 9.84 | 6,713,519.00 | 06/18/2026 Filed 2026-06-23 | SCHEDULE 13D/AAmendment 6 | Open filing 0001104659-26-076853 Dispute this row |
| Peter Evan Harwin Common Stock, $0.00001 par value | 9.99 | 6,808,789.00 | 06/18/2026 Filed 2026-06-23 | SCHEDULE 13D/AAmendment 6 | Open filing 0001104659-26-076853 Dispute this row |
| Tomas Kiselak Common Stock, $0.00001 par value | 9.99 | 6,808,789.00 | 06/18/2026 Filed 2026-06-23 | SCHEDULE 13D/AAmendment 6 | Open filing 0001104659-26-076853 Dispute this row |
| T. Rowe Price Investment Management, Inc. COMMON STOCK | 16.8 | 10,291,220 | 03/31/2026 Filed 2026-04-08 | SCHEDULE 13G/AAmendment 1 | Open filing 0001897612-26-000344 Dispute this row |
| Fairmount Funds Management LLC Common Stock, $0.00001 par value | 9.84 | 6,666,332.00 | 03/26/2026 Filed 2026-03-27 | SCHEDULE 13D/AAmendment 5 | Open filing 0001104659-26-036265 Dispute this row |
| Fairmount Healthcare Fund II L.P. Common Stock, $0.00001 par value | 9.84 | 6,666,332.00 | 03/26/2026 Filed 2026-03-27 | SCHEDULE 13D/AAmendment 5 | Open filing 0001104659-26-036265 Dispute this row |
| Peter Evan Harwin Common Stock, $0.00001 par value | 9.99 | 6,764,974.00 | 03/26/2026 Filed 2026-03-27 | SCHEDULE 13D/AAmendment 5 | Open filing 0001104659-26-036265 Dispute this row |
| Tomas Kiselak Common Stock, $0.00001 par value | 9.99 | 6,764,974.00 | 03/26/2026 Filed 2026-03-27 | SCHEDULE 13D/AAmendment 5 | Open filing 0001104659-26-036265 Dispute this row |
| The Vanguard Group Common Stock | 0 | 0 | 03/13/2026 Filed 2026-03-26 | SCHEDULE 13G/AAmendment 1 | Open filing 0000102909-26-000604 Dispute this row |
| T. Rowe Price Investment Management, Inc. COMMON STOCK | 11.3 | 6,213,827 | 02/28/2026 Filed 2026-03-06 | SCHEDULE 13G | Open filing 0001897612-26-000311 Dispute this row |
| Fairmount Funds Management LLC Common Stock, $0.00001 par value | 9.82 | 5,948,385.00 | 01/22/2026 Filed 2026-01-22 | SCHEDULE 13D/AAmendment 4 | Open filing 0001104659-26-005916 Dispute this row |
| Fairmount Healthcare Fund II L.P. Common Stock, $0.00001 par value | 9.82 | 5,948,385.00 | 01/22/2026 Filed 2026-01-22 | SCHEDULE 13D/AAmendment 4 | Open filing 0001104659-26-005916 Dispute this row |
| Peter Evan Harwin Common Stock, $0.00001 par value | 9.99 | 6,047,027.00 | 01/22/2026 Filed 2026-01-22 | SCHEDULE 13D/AAmendment 4 | Open filing 0001104659-26-005916 Dispute this row |
| Tomas Kiselak Common Stock, $0.00001 par value | 9.99 | 6,047,027.00 | 01/22/2026 Filed 2026-01-22 | SCHEDULE 13D/AAmendment 4 | Open filing 0001104659-26-005916 Dispute this row |
| RTW Investments, LP Common Stock, $0.00001 par value | 4.9 | 2,712,097.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 1 | Open filing 0001493215-26-000028 Dispute this row |
| Roderick Wong Common Stock, $0.00001 par value | 4.9 | 2,712,097.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 1 | Open filing 0001493215-26-000028 Dispute this row |
| Wellington Management Group LLP Common Stock | 8.7 | 4,746,585.00 | 12/31/2025 Filed 2026-02-10 | SCHEDULE 13G/AAmendment 4 | Open filing 0000902219-26-000095 Dispute this row |
| Wellington Group Holdings LLP Common Stock | 8.7 | 4,746,585.00 | 12/31/2025 Filed 2026-02-10 | SCHEDULE 13G/AAmendment 4 | Open filing 0000902219-26-000095 Dispute this row |
| Wellington Investment Advisors Holdings LLP Common Stock | 8.7 | 4,746,585.00 | 12/31/2025 Filed 2026-02-10 | SCHEDULE 13G/AAmendment 4 | Open filing 0000902219-26-000095 Dispute this row |
| Wellington Management Company LLP Common Stock | 8.3 | 4,746,585.00 | 12/31/2025 Filed 2026-02-10 | SCHEDULE 13G/AAmendment 4 | Open filing 0000902219-26-000095 Dispute this row |
| The Vanguard Group Common Stock | 5.21 | 2,857,824 | 12/31/2025 Filed 2026-01-30 | SCHEDULE 13G | Open filing 0000102909-26-000084 Dispute this row |
| Fairmount Funds Management LLC Common Stock, $0.00001 par value | 9.81 | 5,678,239.00 | 10/10/2025 Filed 2025-10-14 | SCHEDULE 13D/AAmendment 3 | Open filing 0001104659-25-099401 Dispute this row |
| Fairmount Healthcare Fund II L.P. Common Stock, $0.00001 par value | 9.81 | 5,678,239.00 | 10/10/2025 Filed 2025-10-14 | SCHEDULE 13D/AAmendment 3 | Open filing 0001104659-25-099401 Dispute this row |
| Peter Evan Harwin Common Stock, $0.00001 par value | 9.99 | 5,776,881.00 | 10/10/2025 Filed 2025-10-14 | SCHEDULE 13D/AAmendment 3 | Open filing 0001104659-25-099401 Dispute this row |
| Tomas Kiselak Common Stock, $0.00001 par value | 9.99 | 5,776,881.00 | 10/10/2025 Filed 2025-10-14 | SCHEDULE 13D/AAmendment 3 | Open filing 0001104659-25-099401 Dispute this row |
| DRIEHAUS CAPITAL MANAGEMENT LLC Common Stock | 4.68 | 2,158,502 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0000938206-25-000048 Dispute this row |
| Wellington Management Group LLP Common Stock | 10.6 | 4,885,146.00 | 07/31/2025 Filed 2025-08-05 | SCHEDULE 13G/AAmendment 3 | Open filing 0000902219-25-000264 Dispute this row |
| Wellington Group Holdings LLP Common Stock | 10.6 | 4,885,146.00 | 07/31/2025 Filed 2025-08-05 | SCHEDULE 13G/AAmendment 3 | Open filing 0000902219-25-000264 Dispute this row |
| Wellington Investment Advisors Holdings LLP Common Stock | 10.6 | 4,885,146.00 | 07/31/2025 Filed 2025-08-05 | SCHEDULE 13G/AAmendment 3 | Open filing 0000902219-25-000264 Dispute this row |
| Wellington Management Company LLP Common Stock | 10.3 | 4,885,146.00 | 07/31/2025 Filed 2025-08-05 | SCHEDULE 13G/AAmendment 3 | Open filing 0000902219-25-000264 Dispute this row |
| FMR LLC COMMON STOCK | 15.0 | 6,907,100.00 | 06/30/2025 Filed 2025-08-06 | SCHEDULE 13G/AAmendment 3 | Open filing 0000315066-25-001957 Dispute this row |
| Abigail P. Johnson COMMON STOCK | 15.0 | 6,907,100.00 | 06/30/2025 Filed 2025-08-06 | SCHEDULE 13G/AAmendment 3 | Open filing 0000315066-25-001957 Dispute this row |
Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.
What was read
2,748,233 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.
Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.
| Filing year | Filings read |
|---|---|
| 2015 | 164,615 |
| 2016 | 222,642 |
| 2017 | 222,009 |
| 2018 | 223,345 |
| 2019 | 216,482 |
| 2020 | 226,343 |
| 2021 | 249,835 |
| 2022 | 231,682 |
| 2023 | 229,674 |
| 2024 | 234,045 |
| 2025 | 235,520 |
| 2026 | 263,828 |
Filings made before the SEC required XML are listed, not extracted.